Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Capital Leases (2016 - 2019)

Enanta Pharmaceuticals (ENTA) has disclosed Capital Leases for 5 consecutive years, with $200000.0 as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Capital Leases fell 31.74% year-over-year to $200000.0, compared with a TTM value of $200000.0 through Sep 2019, down 31.74%, and an annual FY2019 reading of $200000.0, down 31.74% over the prior year.
  • Capital Leases was $200000.0 for Q3 2019 at Enanta Pharmaceuticals, down from $224000.0 in the prior quarter.
  • Across five years, Capital Leases topped out at $529000.0 in Q3 2015 and bottomed at $175000.0 in Q2 2015.
  • Average Capital Leases over 5 years is $364166.7, with a median of $368500.0 recorded in 2017.
  • The sharpest move saw Capital Leases skyrocketed 173.14% in 2016, then crashed 31.74% in 2019.
  • Year by year, Capital Leases stood at $513000.0 in 2015, then dropped by 14.23% to $440000.0 in 2016, then fell by 18.64% to $358000.0 in 2017, then fell by 24.3% to $271000.0 in 2018, then decreased by 26.2% to $200000.0 in 2019.
  • Business Quant data shows Capital Leases for ENTA at $200000.0 in Q3 2019, $224000.0 in Q2 2019, and $249000.0 in Q1 2019.